Compare XEL & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | BDX |
|---|---|---|
| Founded | 1909 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5B | 55.7B |
| IPO Year | N/A | 1962 |
| Metric | XEL | BDX |
|---|---|---|
| Price | $74.44 | $196.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $84.00 | ★ $213.13 |
| AVG Volume (30 Days) | ★ 5.6M | 2.0M |
| Earning Date | 02-05-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.08% | 2.14% |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.27 | ★ 5.82 |
| Revenue | $14,228,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $13.16 | $4.02 |
| Revenue Next Year | $7.63 | $3.37 |
| P/E Ratio | ★ $22.68 | $33.70 |
| Revenue Growth | 3.38 | ★ 8.24 |
| 52 Week Low | $62.58 | $162.29 |
| 52 Week High | $83.01 | $251.99 |
| Indicator | XEL | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 55.10 |
| Support Level | $72.54 | $194.82 |
| Resistance Level | $74.29 | $198.10 |
| Average True Range (ATR) | 1.27 | 3.61 |
| MACD | 0.00 | -0.32 |
| Stochastic Oscillator | 39.51 | 54.88 |
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.